Abstract
In this on-demand webinar, we discuss why it is important to characterize antibodies based on their physical properties not just by what they bind, and how you can easily do the former via mass spectrometry-based protein sequencing.
Key Takeaways
- Antibodies are generally characterized based on what they bind, not their physical properties, limiting researchers’ ability to find and keep good antibodies
$800M is wasted yearly on antibodies that either don’t bind or bind the wrong target (Bradbury & Plückthun, 2015) - Hybridoma sequencing is a great place to start, but ~30% of antibodies have additional chains which cannot be identified just through DNA sequencing
- In taking an MS/MS approach you can characterize and immortalize your best antibodies from the protein itself, while identifying additional chains and relevant post-translational modifications
Newsletter for All Things Protein Sequencing
Breakthrough Bispecific Antibody R&D Techniques, Apr 20 11:00am EST.
Talk to Our Scientists.
We Have Sequenced 5000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 5000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics